In the normal aging process, both cumulative oxidative stress and low-grade inflammation (inflammaging) play key roles. Moreover, advanced age is associated with increased incidence of chronic diseases, such as cardiovascular and neurodegenerative disorders and cancer, which share oxidative stress and inflammation as pivotal players. It is evident that oxidative stress and inflammation have interdependent mechanisms, and are able to induce and exacerbate each other. Indeed, aging has been associated with an increased production of reactive oxygen species and a concomitant antioxidant systems’ impairment, favouring inflammaging. This Special Issue is devoted to disentangling and understanding some of these intricate mechanisms, in order to identify the major contributor(s) of ageing and age-related diseases. In addition, multidisciplinary approaches are strongly desirable to pinpoint new strategies able to interfere with oxidative stress and inflammaging in order to delay the onset of age-related pathologies and provide a healthy lifespan of aging population in the long run.
Prof. Dr. Daniela MontiGuest Editor
Deadline for manuscript submissions: 31 October 2018
Visit the special issue website: http://www.mdpi.com/journal/ijms/special_issues/inflammaging_oxidative_stress
G protein-coupled receptors (GPCR) are seven transmembrane proteins initiating a wide range of signals that affect numerous physiological and pathological processes. As therapeutic targets, they have accounted for nearly 30% of the successful receptor-based drug treatments of disorders ranging from hypertension and allergy to clinical depression.
While a great deal of information has been gathered with regard to their structure, classification, signaling properties and unique mode of "biased" (or "functionally selective") GPCR signalling pathways, it is now timely to define their role in tumor biology. Despite the fact that many GPCRs belonging to different subclasses have emerged with central roles in cancer development, as yet no known cancer-therapeutic GPCR-targeted drug is in clinical practice. Of note, the genomic, transcriptomic and immunohistochemical analyses of tumour tissues has revealed a 20% incidence of GPCR mutations in many cancers; and an upregulation of wild-type GPCRs has been documented, due to multiple mechanisms. Thus, an increased understanding of the ways GPCRs can act as cancer drivers is highly warranted.
The Need Met by This Special Issue
Given the above information, it is thus the goal of this Special Issue to highlight the roles that GPCRs may play in tumor growth, invasion, metastasis and survival at both the primary and secondary metastatic sites, including the cancer stem cell niche. It is intended to emphasize the great potential of targeting GPCRs to treat cancer.
For each of a number of selected GPCRs, including the adhesion and frizzled (FZD) families, along with the Class A, B and C receptors, contributors are asked to provide a concise overview of the current receptor cell biology, their potential as cancer drivers and their potential as therapeutic targets in the setting of cancer.
Prof. Dr. Rachel Bar-ShavitProf. Dr. Morley D. HollenbergGuest Editors
Deadline for manuscript submissions: 30 September 2018
Visit the website: http://www.mdpi.com/journal/ijms/special_issues/gpcr_cancer